Europe Intragastric Balloon Market Share was valued at USD 11.0 million in 2019 and is expected to witness over 20.0% CAGR from 2019 to 2026. Single intragastric balloon segment accounted for revenue of more than USD 7.0 million.
Get more details on this report - Request Free Sample PDF
Intragastric balloons have advantages over other surgical treatment procedures for obesity. These advantages include reduction in hospital stay, no requirement of any incision for administration of intragastric balloons and absence of any other complications such as blood loss. Other surgical procedures for weight loss such as sleeve gastrectomy and gastric bypass involve removal and bypassing of certain portion of the stomach. As the number of complications associated with surgical treatments is high, patients prefer non-surgical treatment options, thus propelling industry growth.
Low cost of the component considerably increases adoption rate of intragastric balloons among patients suffering from obesity. The cost of gastric balloon procedure is about one third the cost of bariatric surgery procedure. In addition to cost-effectivity, intragastric balloon procedure is minimally invasive in comparison to other bariatric procedures. The low price of intragastric balloon procedure for obesity reduction as compared to other procedures such as gastric bypass, sleeve gastrectomy and adjustable gastric band will significantly boost the market growth.
Europe Market, By Product
Single intragastric balloon segment accounted for revenue of more than USD 7.0 million. Various technological advancements associated with the system such as patients being able to swallow the balloons like a regular pill followed by inflation coupled with rapid weight loss will drive the product uptake. Furthermore, improved outcomes with the help of single intragastric balloons regarding weight loss will augment the segmental growth over the forecast years.
Europe Market, By Filling Material
Saline-filled balloon dominated the overall intragastric balloon market in 2019 with market share of more than 60.0%. The largest share of saline-filled balloon is attributed to its wide applications in the treatment of obesity which helps in rapid weight loss. Growing prevalence of chronic conditions such as diabetes, obesity will further augment adoption rate of intragastric balloon over the forecast timeframe.
Europe Market, By End-use
Hospitals segment is forecasted to expand at 19.0% during the forecast timeframe. High growth rate is due to increasing number of patient pool seeking obesity treatment in the hospitals. Availability of skilled healthcare personnel and advanced devices for treatment of obesity will favor segmental growth in the future. Penetration of various hospitals in developing countries by opening clinics initially to cater to sub-urban and tier-2 cities demand should drive clinics end-use segment growth.
Europe Market, By Country
France accounted for the largest market share of about 30% in the region. The key factor driving the France intragastric balloon industry growth includes high adoption of non-surgical treatments coupled with rising prevalence of obesity. Moreover, France is one of the leading countries in terms of number of bariatric procedures. High healthcare expenditure, growing awareness about obesity and presence of large number of clinics offering bariatric treatments will contribute to the higher market size.
Competitive Market Share
Major companies operating in the European intragastric balloon market include Apollo Endosurgery, Allurion Technologies, Obalon Therapeutics Districlass Medical, and Reshape Lifesciences. Other players include Spatz FGIA Inc., Helioscopie, MedSil, Lexel Medical and Endalis. Companies are adopting numerous strategies to increase the market share. For instance, in August 2017, Apollo Endosurgery Inc., received CE Mark approval for its ORBERA365 Balloon system. This approval enabled the company to market its flagship product in the well-established European market, thereby ensuring a competitive edge over its competitors.
Europe Intragastric Balloon Market Background
Intragastric balloon were introduced in Europe in the early 1980s. However, the initial balloons had large number of severe risks and complications. Various technological advances since the introduction of first intragastric balloon have led to development of novel intragastric balloons. For instance, the Elipse intragastric balloon, developed by Allurion Technologies, is the first product that does not require removal or implantation procedure. The product is swallowed by the patient in the pill-form, which is then inflated once it reaches in the stomach. After about 4 months, the device valve opens automatically, deflating the balloon that can be easily excreted. Such advances will drive the Europe intragastric balloon industry across the forecast timeframe.